Targeting cancer on the basis of genetic mutations, upregulation of oncogenes or defect in tumor suppressor genes have been proven difficult due to the genetic instability and heterogeneity of human tumors. Breakthroughs in cancer metabolism of the last two decades have brought some insights on tumor metabolic reprogramming and plasticity that have been proposed as an alternative for narrowing genetic heterogeneity and unresponsiveness to therapy. However, cancer metabolism is still underexplored clinically as many questions remain open on the vast spectrum of metabolic strategies a tumor can exploit to grow, migrate and evade treatments. Therefore, understanding the complex interactions between tumor preferential metabolic pathways, mutational landscape and microenvironmental influences is mandatory for the development and discovery of novel therapeutic strategies for cancer patients.
In this Research Topic, we aim to gather studies bringing new insights on the multifacets of tumor heterogeneity and its impact on amino-acids (AAs) metabolism. Novel studies deciphering tumor metabolic complexity and/or its interplay with oncogenic activation or suppression are welcome. A particular consideration will be given to papers that would provide scientific advances in AAs metabolism, metabolic adaptation and oncogenic activation during spontaneous tumor development or treatment escape. Toward these aims, we encourage submissions that focus on mechanistic hints and the development and validation of novel anticancer approaches, which include, but are not limited to, AAs metabolism, hypoxia, tumor heterogeneity, genetic and epigenetic regulations dependent on AAs-derived metabolites and combination therapies that explore the targeting of signaling cascades and tumor metabolism.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
Targeting cancer on the basis of genetic mutations, upregulation of oncogenes or defect in tumor suppressor genes have been proven difficult due to the genetic instability and heterogeneity of human tumors. Breakthroughs in cancer metabolism of the last two decades have brought some insights on tumor metabolic reprogramming and plasticity that have been proposed as an alternative for narrowing genetic heterogeneity and unresponsiveness to therapy. However, cancer metabolism is still underexplored clinically as many questions remain open on the vast spectrum of metabolic strategies a tumor can exploit to grow, migrate and evade treatments. Therefore, understanding the complex interactions between tumor preferential metabolic pathways, mutational landscape and microenvironmental influences is mandatory for the development and discovery of novel therapeutic strategies for cancer patients.
In this Research Topic, we aim to gather studies bringing new insights on the multifacets of tumor heterogeneity and its impact on amino-acids (AAs) metabolism. Novel studies deciphering tumor metabolic complexity and/or its interplay with oncogenic activation or suppression are welcome. A particular consideration will be given to papers that would provide scientific advances in AAs metabolism, metabolic adaptation and oncogenic activation during spontaneous tumor development or treatment escape. Toward these aims, we encourage submissions that focus on mechanistic hints and the development and validation of novel anticancer approaches, which include, but are not limited to, AAs metabolism, hypoxia, tumor heterogeneity, genetic and epigenetic regulations dependent on AAs-derived metabolites and combination therapies that explore the targeting of signaling cascades and tumor metabolism.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.